Trial Profile
A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2017
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Essential hypertension; Heart failure; Hypertension; Kidney disorders
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals Corporation
- 18 Aug 2017 New trial record